Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD.
Publication/Presentation Date
6-1-2023
Abstract
BACKGROUND: The safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown.
METHODS: We compared symptoms following a third SARS-CoV-2 mRNA vaccine dose with symptoms after the second dose in IBD.
RESULTS: The study group included 594 patients (70% female, 58% BNT162b2). Overall, 41% reported symptoms after a third dose. Symptom frequency and severity were lower after the third dose relative to the second dose for every organ system, except for gastrointestinal symptoms which were marginally worse.
CONCLUSION: The frequency and severity of symptoms after a third mRNA vaccine dose are generally similar or milder than after a second dose for most organ systems.
Volume
29
Issue
6
First Page
883
Last Page
887
ISSN
1536-4844
Published In/Presented At
Li, D., Debbas, P., Mujukian, A., Cheng, S., Braun, J., McGovern, D. P. B., Melmed, G. Y., & CORALE-IBD Study Group (2023). Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD. Inflammatory bowel diseases, 29(6), 883–887. https://doi.org/10.1093/ibd/izac174
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
35998072
Department(s)
Administration and Leadership
Document Type
Article